Navigation Links
Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
Date:1/15/2008

Collaboration with CDC to Focus on Testing of Juvaris JVRS-100 as an Adjuvant with existing H5N1 vaccine for dose-sparing and cross protection

PLEASANTON, Calif., Jan. 15 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today that The Centers for Disease Control and Prevention and Juvaris BioTherapeutics, Inc. have entered into a Cooperative Research and Development Agreement (CRADA) for the evaluation of a JVRS-100 adjuvanted H5N1 pandemic influenza vaccine. The ability of JVRS-100 to aid in the induction of a protective antibody response to the H5N1 vaccine at low doses of vaccine will be confirmed. This collaborative study will determine if the use of the Juvaris JVRS-100 adjuvant will extend the limited supply of H5N1 vaccines in the event of a pandemic.

In preparation for the possibility of an influenza pandemic caused by an H5N1 avian influenza virus that has obtained the ability to be easily transmitted from person to person, several strains of H5N1 viruses have been used to prepare killed-virus vaccines. Vaccine trials in people testing the immunogenicity of these pre-pandemic vaccines have shown that high vaccine doses are required to produce an antibody response that is believed to be protective. In order to lower the dose of vaccine and extend the supply of available vaccine, a number of immune boosters known as adjuvants are being tested.

"Although the principal commercial value of JVRS-100 will be as a mono-immunotherapy, we are pleased to enter into this CRADA with CDC for testing of the JVRS-100 as an adjuvant for potential extension of the current supply of H5N1 vaccine," said Martin D. Cleary, Co-founder, President and CEO of Juvaris. "In preclinical studies using seasonal influenza vaccine our adjuvant can decrease the amount of vaccine necessary to induce protective antibody immunity up to fifty-fold, which would be beneficial in case of limited vaccine supply during an influenza pandemic. Furthermore, preclinic
'/>"/>

SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... (NYSE: RMD ) today announced results for its ... was $453.1 million, a 9 percent increase compared with ... increase on a constant currency basis).  Net income was ... 2014.  Diluted earnings per share for the quarter were ... The results for the quarter ended ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... BETHLEHEM, Pa., Oct. 20, 2011 MedClean Technologies ... leading provider of onsite technology for the treatment ... of confidential documents and related media, today announced ... environmental firm specializing in consulting, waste disposal, engineering ...
... Oct. 20, 2011 Dey Pharma L.P., a subsidiary of ... the U.S. Patent and Trademark Office (PTO) has issued Reexamination ... (Formoterol Fumarate) Inhalation Solution 20 mcg/2mL vial thereby confirming ... Pharmaceuticals, requested the PTO to re-examine these patents, which now ...
Cached Medicine Technology:MedClean Technologies Partners With Triumvirate Environmental 2MedClean Technologies Partners With Triumvirate Environmental 3Mylan's Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents 2
(Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Brig and Lita ... are announcing the unification of their Healthy Home mission with the HOPE Movement of ... years, the founders of both companies have agreed to join their missions of purpose ...
(Date:8/1/2015)... Atlanta, GA (PRWEB) , ... August 01, 2015 , ... ... iPhone app that is free to download on the Apple AppStore. , The ... energy levels, even mood, thus acting as a tool to view personal health and ...
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive ... the Appalachian Trail by stepping off Springer Mountain and heading north. Since that ... 26th Phil reached Connecticut and was greeted by friends and family. He visited CCAR ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... cancer-causing virus enables it to bypass immune systems and infect the ... that the virus persists in the host. // ... is made by the human T cell leukemia virus type 1 ... of AIDS. ,The findings indicate that HBZ enhanced the ability ...
... has developed an electronic device that alerts women whether or not ... unwanted pregnancy. // ,The Remember Device developed by Lai ... when it is time to take her pill with a choice ... or a dual alarm vibrate mode, reported online edition of BBC ...
... more than Rs 750 crore over next four years ... Hooda said today. // ,The Congress government ... the village level and concerted efforts were being made ... he said at a rally in Jasuar Kheri village ...
... over the world will meet at Mount Abu in September ... India and how preventive measures can help control its early ... Preventive Cardiology is being held from September 22 at Mount ... issues and newer technologies besides crystallizing recent trends and newer ...
Statistics released by the Scottish Executive show that around 2.9 million clean needles were dispensed for drug users, but only 1.9 million were returned thus sparking a shortage of a million needles...
... minister of Health Manto Tshabalala-Msimang said that the traditional-medicines ... budget. A workshop was conducted on traditional-medicine in Benoni ... an interim traditional-health council. // ,Her department ... the problem lies with the allocation of money. She ...
Cached Medicine News:Health News:Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells 2Health News:Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells 3Health News:World Cong On Preventive Cardiology In Sept 2
Research Series 2100 Adjustable-volume Pipette, 20-200 l, single-channel with adjustable-volume setting...
... the #1 Pipettor for sub-microliter pipetting ... reliability. Continuously adjustable. Features lPLUS, a ... interchangeable ejector buttons to fit large ... pipet tip ejector with three different ...
... new Finnpipette Focus from Thermo Labsystems was ... performance. Advanced features such as the ... volume adjustment on microvolumes help to define ... channel pipettes. The new interchangeable handle plate ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: